{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T07:35:31Z","timestamp":1792740931431,"version":"4.5.0"},"reference-count":34,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T00:00:00Z","timestamp":1589500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/bmj.com\/coronavirus\/usage"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Ethics"],"accepted":{"date-parts":[[2020,5,1]]},"published-print":{"date-parts":[[2020,7]]},"abstract":"<jats:p>Vaccines are a powerful measure to protect the health of individuals and to combat outbreaks such as the COVID-19 pandemic. An ethical dilemma arises when one effective vaccine has been successfully developed against an epidemic disease and researchers seek to test the efficacy of another vaccine for the same pathogen in clinical trials involving human subjects. On the one hand, there are compelling reasons why it would be unethical to trial a novel vaccine when an effective product exists already. First, it is a firm principle of medical ethics that an effective treatment or vaccine should not be withheld from patients if their life may depend on it. Second, since epidemic outbreaks often emerge in settings with less-resourced health systems, there is a pronounced risk that any trial withholding an effective vaccine would disproportionately affect the vulnerable populations that historically have been exploited for biomedical research. Third, clinical trials for novel vaccines may be at odds with efforts to control active outbreaks. On the other hand, it may be justified to conduct a trial for a candidate vaccine if it is expected to have certain advantages compared with the existing product. This essay discusses key factors for comparing vaccines against epidemic pathogens, including immunological, logistical and economic considerations. Alongside a case study of the development of vaccines for Ebola, the essay seeks to establish a general framework that should be expanded and populated by immunologists, epidemiologists, economists and bioethicists, and ultimately could be applied to the case of COVID-19 vaccines.<\/jats:p>","DOI":"10.1136\/medethics-2020-106235","type":"journal-article","created":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T18:01:40Z","timestamp":1589565700000},"page":"465-469","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Ethical considerations for epidemic vaccine trials"],"prefix":"10.1136","volume":"46","author":[{"given":"Joshua Teperowski","family":"Monrad","sequence":"first","affiliation":[{"name":"Program in Ethics, Politics, and Economics, Yale University, New Haven, CT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2020,5,15]]},"reference":[{"issue":"11","key":"2025092414002483000_46.7.465.1","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.2105\/AJPH.2018.304581","article-title":"The Spanish flu, epidemics, and the turn to biomedical responses","volume":"108","author":"Schwartz","year":"2018","journal-title":"Am J Public Health"},{"issue":"33","key":"2025092414002483000_46.7.465.2","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1016\/j.vaccine.2017.06.003","article-title":"The complexity and cost of vaccine manufacturing - An overview","volume":"35","author":"Plotkin","year":"2017","journal-title":"Vaccine"},{"key":"2025092414002483000_46.7.465.3","unstructured":"National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, et al . Integrating clinical research into epidemic response. Washington (DC: National Academies Press (US), 2017."},{"key":"2025092414002483000_46.7.465.4","unstructured":"The Council for International Organizations of Medical Sciences (CIOMS) . International ethical guidelines for biomedical research involving human subjects. Geneva, 2016."},{"issue":"9","key":"2025092414002483000_46.7.465.5","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1080\/21645515.2016.1272744","article-title":"New ethical considerations in vaccine trials","volume":"13","author":"Molyneux","year":"2017","journal-title":"Hum Vaccin Immunother"},{"issue":"24","key":"2025092414002483000_46.7.465.6","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1016\/j.vaccine.2020.04.039","article-title":"Extraordinary diseases require extraordinary solutions","volume":"38","author":"Plotkin","year":"2020","journal-title":"Vaccine"},{"key":"2025092414002483000_46.7.465.7","doi-asserted-by":"crossref","unstructured":"Eyal N , Lipsitch M , Smith PG . Human challenge studies to accelerate coronavirus vaccine licensure. J Infect Dis 2020;2.doi:10.1093\/infdis\/jiaa152","DOI":"10.1093\/infdis\/jiaa152"},{"key":"2025092414002483000_46.7.465.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61734-7"},{"key":"2025092414002483000_46.7.465.9","doi-asserted-by":"publisher","DOI":"10.1111\/bioe.12467"},{"key":"2025092414002483000_46.7.465.10","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)32621-6"},{"key":"2025092414002483000_46.7.465.11","doi-asserted-by":"crossref","unstructured":"Metzger WG , Vivas-Mart\u00ednez S . Questionable efficacy of the rVSV-ZEBOV Ebola vaccine. The Lancet 2018;391(10125).doi:10.1016\/S0140-6736(18)30560-9","DOI":"10.1016\/S0140-6736(18)30560-9"},{"key":"2025092414002483000_46.7.465.12","unstructured":"World Health Organization . Preliminary results on the efficacy of rVSV-ZEBOV-GP Ebola vaccine using the ring vaccination strategy in the control of an Ebola outbreak in the Democratic Republic of the Congo: an example of integration of research into epidemic response, 2019. Available: https:\/\/www.who.int\/csr\/resources\/publications\/ebola\/ebola-ring-vaccination-results-12-april-2019.pdf?ua=1"},{"key":"2025092414002483000_46.7.465.13","unstructured":"Mahamba F , Kelland K , Ross A . Deployment of second Ebola vaccine would not be quick fix, experts warn. Reuters, 2019. Available: https:\/\/www.reuters.com\/article\/us-health-ebola-vaccine-idUSKCN1UK1KR [Accessed 20 Mar 2020]."},{"key":"2025092414002483000_46.7.465.14","doi-asserted-by":"publisher","DOI":"10.1126\/science.364.6447.1221"},{"key":"2025092414002483000_46.7.465.15","unstructured":"Branswell H . Debate over whether to test second Ebola vaccine turns acrimonious. STAT 2019 https:\/\/www.statnews.com\/2019\/07\/17\/debate-testing-second-ebola-vaccine\/"},{"key":"2025092414002483000_46.7.465.16","unstructured":"CEPI . Global Consortium working with DRC government to introduce second Ebola vaccine. CEPI, 2019. Available: https:\/\/cepi.net\/news_cepi\/global-consortium-working-with-drc-government-to-introduce-second-ebola-vaccine\/ [Accessed 20 Mar 2020]."},{"key":"2025092414002483000_46.7.465.17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198707163170304"},{"key":"2025092414002483000_46.7.465.18","unstructured":"Beauchamp TL , Childress JF . Principles of Biomedical Ethics. 7 edition. New York: Oxford University Press, 2012."},{"key":"2025092414002483000_46.7.465.19","unstructured":"National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research . The Belmont report: ethical principles and guidelines for the protection of human subjects of research. Bethesda, MD, 1979. Available: https:\/\/www.hhs.gov\/ohrp\/regulations-and-policy\/belmont-report\/read-the-belmont-report\/index.html"},{"key":"2025092414002483000_46.7.465.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-8519.2008.00631.x"},{"key":"2025092414002483000_46.7.465.21","doi-asserted-by":"publisher","DOI":"10.1017\/S0963180109090203"},{"issue":"1","key":"2025092414002483000_46.7.465.22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF03391665","article-title":"Ethical failures and history lessons: the U.S. public health service research studies in tuskegee and Guatemala","volume":"34","author":"Reverby","year":"2012","journal-title":"Public Health Rev"},{"key":"2025092414002483000_46.7.465.23","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m734"},{"key":"2025092414002483000_46.7.465.24","unstructured":"Washington HA . Deadly monopolies: the shocking corporate takeover of life Itself-And the consequences for your health and our medical future. Random House, 2011."},{"issue":"12","key":"2025092414002483000_46.7.465.25","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1007\/s10461-019-02620-7","article-title":"Consent challenges and psychosocial distress in the scale-up of voluntary medical male circumcision among adolescents in Western Kenya","volume":"23","author":"Luseno","year":"2019","journal-title":"AIDS Behav"},{"key":"2025092414002483000_46.7.465.26","unstructured":"Beckstead N . On the overwhelming importance of shaping the far future (Doctoral dissertation). Rutgers University-Graduate School-New Brunswick, 2013."},{"issue":"4","key":"2025092414002483000_46.7.465.27","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1089\/hs.2017.0044","article-title":"Human agency and global catastrophic Biorisks","volume":"15","author":"Millett","year":"2017","journal-title":"Health Secur"},{"key":"2025092414002483000_46.7.465.28","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.20644"},{"key":"2025092414002483000_46.7.465.29","unstructured":"Branswell H . A spot of good news in Ebola crisis: vaccine supplies are expected to last. STAT, 2019. Available: https:\/\/www.statnews.com\/2019\/01\/22\/some-needed-good-news-on-ebola-vaccine-supplies-are-expected-to-last\/ [Accessed 18 Nov 2019]."},{"key":"2025092414002483000_46.7.465.30","unstructured":"SFRC Subcommittee on Africa and Global Health . Ebola hearing. Washington, D.C, 2019. Available: https:\/\/www.foreign.senate.gov\/hearings\/confronting-ebola-addressing-a-21st-century-global-health-crisis [Accessed 20 Mar 2020]."},{"key":"2025092414002483000_46.7.465.31","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2011.0403"},{"key":"2025092414002483000_46.7.465.32","doi-asserted-by":"publisher","DOI":"10.1093\/phe\/phn016"},{"key":"2025092414002483000_46.7.465.33","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7264.824"},{"key":"2025092414002483000_46.7.465.34","doi-asserted-by":"publisher","DOI":"10.1086\/381709"}],"updated-by":[{"DOI":"10.1136\/medethics-2020-106235corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000}}],"container-title":["Journal of Medical Ethics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/medethics-2020-106235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T21:00:38Z","timestamp":1758747638000},"score":1,"resource":{"primary":{"URL":"https:\/\/jme.bmj.com\/lookup\/doi\/10.1136\/medethics-2020-106235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,15]]},"references-count":34,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2020,6,29]]},"published-print":{"date-parts":[[2020,7]]}},"alternative-id":["10.1136\/medethics-2020-106235"],"URL":"https:\/\/doi.org\/10.1136\/medethics-2020-106235","relation":{},"ISSN":["0306-6800","1473-4257"],"issn-type":[{"value":"0306-6800","type":"print"},{"value":"1473-4257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,15]]}}}